ArticleDiabetes, obesity & metabolism2020

A glycosylated Fc-fused glucagon-like peptide-1 receptor agonist exhibits equivalent glucose lowering to but fewer gastrointestinal side effects than dulaglutide.

In Bok An et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.